Human Health

Modern biotechnology provides breakthrough products and technologies to combat debilitating diseases. Innovative medicines and cures help people lead longer, healthier lives and positively impact society by providing economic value far beyond their cost. To ensure these transformative therapies get to the people who need them, BIO is committed to advancing policies that foster innovation, fuel investment and encourage the entrepreneurial spirit that has made America the global leader in this cutting-edge field.

Tears of Sorrow, Tears of Joy

Drug Cost Facts

Advocate Toolkit

BIOAction

Letters, Comments & Testimony

CSBA Letter to Congressional Leadership on Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program

September 9, 2024

BIO Comments to the Minnesota Department of Health on Drugs of Substantial Public Interest: Draft Methodology for Public Comment

May 9, 2024

BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.

BIO Comments to HHS's Centers for Medicare & Medicaid Services in response to their Information Collection Request (ICR) on the Part C and Part D Medicare Prescription Payment Plan

April 19, 2024

The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.

Press Releases

New Season of “I am BIO” Podcast Explores Patient Stories, Weight Loss Drugs, Food Security, and More

September 5, 2024

WASHINGTON - (September 5, 2024) –The Biotechnology Innovation Organization (BIO) will launch the fall season of the award-winning “I am BIO” podcast on September 10. Now entering its fifth year, the podcast explores the intersection of biotechnology, life sciences, environment, and agriculture. “I…

BIO Commends FDA Plan to Establish a Rare Disease Innovation Hub to advance rare disease collaboration, treatments

July 17, 2024

July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative approaches to expedite the development and approval of…

BIO Applauds Introduction of Bipartisan Legislation to Reauthorize Program That Encourages Rare Pediatric Disease Research

June 20, 2024

BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating Hope Reauthorization Act to reauthorize the Rare…

Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Join BIOAction

BIO Advocacy Toolkit

We’ve made it easier for you to access information and share content about biotechnology and prescription medicines. Learn more about dozens of topics and then share information you discover on Twitter, Facebook, and LinkedIn.

Discover More